Dr. Reddy’s launches Wellbutrin XL, Skelaxin generics
HYDERABAD, India, and PRINCETON, N.J. — Dr. Reddy’s Laboratories has introduced two generics this week. The company on Wednesday announced the launch of its generics of Wellbutrin XL (bupropion hydrochloride) extended-release tablets and Skelaxin (metaxalone) tablets.
The Wellbutrin XL generic is indicated as a treatment for major depressive disorder and for prevention of seasonal major depressive episodes in patients with seasonal affective disorder. The Dr. Reddy’s generic will be available in 150- and 300-mg dosage strength tablets, both of which are available in 30-, 90- and 500-count bottles. The drug had U.S. brand and generic sales of $754 million for the 12 months ended July 2017, according to QuintilesIMS data.
The Dr. Reddy’s generic of Skelaxin is indicated as an adjunctive therapy for relief of discomfort associated with acute, painful musculoskeletal conditions. The generic will be available in 100-count bottles of 800-mg dosage strength tablets. The drug had U.S. brand and generic sales of $139 million for the 12 months ended July 2017, according to QuintilesIMS data.